home.social

#mct8 — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #mct8, aggregated by home.social.

fetched live
  1. Johannes W. Dietrich @[email protected] ·

    #MCT8 deficiency or #Allan_Herndon_Dudley syndrome is a rare disorder of #thyroid hormone transport, leading to severe neurodevelopmental delay. See our newest paper for monitoring recommendations.

    pubmed.ncbi.nlm.nih.gov/419265
    doi.org/10.1159/000551857
    livivo.de/doc/M41926547

    #mct8 #allan_herndon_dudley #thyroid
  2. Johannes W. Dietrich @[email protected] ·

    #MCT8 deficiency or #Allan_Herndon_Dudley syndrome is a rare disorder of #thyroid hormone transport, leading to severe neurodevelopmental delay. See our newest paper for monitoring recommendations.

    pubmed.ncbi.nlm.nih.gov/419265
    doi.org/10.1159/000551857
    livivo.de/doc/M41926547

    #mct8 #allan_herndon_dudley #thyroid
  3. Johannes W. Dietrich @[email protected] ·

    #MCT8 Deficiency, or Allan-Herndon-Dudley syndrome, is a rare severe disorder of #thyroid hormone transport. In our newest paper, we review the state of the art on pathophysiology, diagnosis & treatment.

    pubmed.ncbi.nlm.nih.gov/415088
    doi.org/10.1210/clinem/dgaf707
    livivo.de/doc/M41508830

    #mct8 #thyroid
  4. Johannes W. Dietrich @[email protected] ·

    #MCT8 Deficiency, or Allan-Herndon-Dudley syndrome, is a rare severe disorder of #thyroid hormone transport. In our newest paper, we review the state of the art on pathophysiology, diagnosis & treatment.

    pubmed.ncbi.nlm.nih.gov/415088
    doi.org/10.1210/clinem/dgaf707
    livivo.de/doc/M41508830

    #mct8 #thyroid
  5. Biostock @[email protected] ·

    Egetis initiates rolling NDA for Emcitate

    Egetis Therapeutics has started a rolling New Drug Application (NDA) to the US FDA for Emcitate (tiratricol) for the treatment of MCT8 deficiency. This follows a pre-NDA meeting on October 21 where the FDA confirmed eligibility based on available data and granted the rolling review process.

    #biotech #FDA #MCT8 #Egetis

    #biotech #fda #mct8 #egetis
  6. Biostock @[email protected] ·

    Egetis initiates rolling NDA for Emcitate

    Egetis Therapeutics has started a rolling New Drug Application (NDA) to the US FDA for Emcitate (tiratricol) for the treatment of MCT8 deficiency. This follows a pre-NDA meeting on October 21 where the FDA confirmed eligibility based on available data and granted the rolling review process.

    #biotech #FDA #MCT8 #Egetis

    #biotech #fda #mct8 #egetis
  7. Johannes W. Dietrich @[email protected] ·

    The Allan-Herndon-Dudley syndrome is a rare #thyroid disease caused by #MCT8 mutation, leading to severe consequences. Many aspects of its metabolic signature are poorly understood. In our newest paper, we present a theory that may provide new insights. pubmed.ncbi.nlm.nih.gov/365680

    #mct8 #thyroid
  8. Johannes W. Dietrich @[email protected] ·

    The Allan-Herndon-Dudley syndrome is a rare #thyroid disease caused by #MCT8 mutation, leading to severe consequences. Many aspects of its metabolic signature are poorly understood. In our newest paper, we present a theory that may provide new insights. pubmed.ncbi.nlm.nih.gov/365680

    #mct8 #thyroid